Evidence map›Paper›PMID 37731693›Full record

ReviewRSC medicinal chemistry2023

Restoring susceptibility to aminoglycosides: identifying small molecule inhibitors of enzymatic inactivation.

Angel J Magaña, Jan Sklenicka, Clemencia Pinilla, Marc Giulianotti, Prem Chapagain, Radleigh Santos, Maria Soledad Ramirez, Marcelo E Tolmasky

Abstract readReview
In one paragraph

Review in RSC medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Susceptibility ofAntibiotics (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Insights into Kinases of ESKAPE Pathogens for Therapeutic Interventions.Cardiovascular & hematological agents in medicinal chemistry · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Angel J MagañaCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton Fullerton CA 92831 USA mtolmasky@fullerton.edu.
Jan SklenickaCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton Fullerton CA 92831 USA mtolmasky@fullerton.edu.
Clemencia PinillaCenter for Translational Science, Florida International University Port St. Lucie FL 34987 USA.
Marc GiulianottiCenter for Translational Science, Florida International University Port St. Lucie FL 34987 USA.
Prem ChapagainDepartment of Physics, Florida International University Miami FL 33199 USA.ORCID https://orcid.org/0000-0002-0999-4975
Radleigh SantosDepartment of Mathematics, Nova Southeastern University Fort Lauderdale FL 33314 USA.
Maria Soledad RamirezCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton Fullerton CA 92831 USA mtolmasky@fullerton.edu.
Marcelo E TolmaskyCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton Fullerton CA 92831 USA mtolmasky@fullerton.edu.ORCID https://orcid.org/0000-0002-6298-7811

Funding

DEALING WITH ANTIBIOTIC RESISTANCE--ANTISENSE TECHNOLOGYR15AI047115 · NIAID · CALIFORNIA STATE UNIVERSITY FULLERTON · PI TOLMASKY, MARCELO E · 2000 to 2022
$1.8M
Identifying host human products responsible for natural transformation of resistance traits in Acinetobacter sppSC3GM125556 · NIGMS · CALIFORNIA STATE UNIVERSITY FULLERTON · PI RAMIREZ, MARIA SOLEDAD · 2018 to 2025
$851k
NIAID NIH HHS R15 AI047115NIGMS NIH HHS SC3 GM125556
6 · The paper itself

Abstract

Growing resistance to antimicrobial medicines is a critical health problem that must be urgently addressed. Adding to the increasing number of patients that succumb to infections, there are other consequences to the rise in resistance like the compromise of several medical procedures and dental work that are heavily dependent on infection prevention. Since their introduction in the clinics, aminoglycoside antibiotics have been a critical component of the armamentarium to treat infections. Still, the increase in resistance and their side effects led to a decline in their utilization. However, numerous current factors, like the urgent need for antimicrobials and their favorable properties, led to renewed interest in these drugs. While efforts to design new classes of aminoglycosides refractory to resistance mechanisms and with fewer toxic effects are starting to yield new promising molecules, extending the useful life of those already in use is essential. For this, numerous research projects are underway to counter resistance from different angles, like inhibition of expression or activity of resistance components. This review focuses on selected examples of one aspect of this quest, the design or identification of small molecule inhibitors of resistance caused by enzymatic modification of the aminoglycoside. These compounds could be developed as aminoglycoside adjuvants to overcome resistant infections.

Identifiers

PMID37731693
PMCPMC10507813

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.